AI-Powered News AnalysisCompare coverage across the political spectrum
Back to Dashboard
Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters

Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters

Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters

April 10, 2026 at 10:20 PM Original source
6 agencies covered this story

Coverage by Political Leaning

See how different sides of the spectrum reported this story

Left
0 articles
No coverage
Lean Left
0 articles
No coverage
Center
6 articles
Lean Right
0 articles
No coverage
Right
0 articles
No coverage

Key People

No people linked to this story

All Coverage

Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters
Reutersvia rss

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQV0xhbE5EbkRDa2l2OEdTdkhHRzlZU1cwdUM4bWt6ZGVTTWNIeFFUdHhDaW9SOHBiM3A3eV9VVTZoNXlRM0pNSk5adXJ1Vkw1SDZqSWI5aGlfT3B1VThsV21acFBVUU1RTE9oZXNSbHRMUlZTSzhNTGdXQTJELUgycm1QM0d5cGdQdlNicURjZEZ5LXVxa2t6MWh0aEI2N1o0UVM1X2VxMDAtb0t1T0pzSFdNTQ?oc=5" target="_blank">Replimune's drug for advanced skin cancer fails to win FDA nod again</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

100%
Replimune's drug for advanced skin cancer fails to win FDA nod again
MarketScreener Indiavia ai

The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.

80%
Replimune's drug for advanced skin cancer fails to win FDA nod again
TradingView Newsvia ai

The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.

80%
Replimune's drug for advanced skin cancer fails to win FDA nod again
MarketScreener Canadavia ai

The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.

80%
Replimune’s drug for advanced skin cancer fails to win FDA nod again
Y94via ai

The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.

80%
Replimune’s drug for advanced skin cancer fails to win FDA nod again
1027 WBOWvia ai

The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.

80%